Cycle Pharma - About the company
Cycle Pharma is a funded company based in Cambridge (United Kingdom), founded in 2012. It operates as a Small molecule drug reformulation and repurposing for orphan indications. Cycle Pharma has raised an undisclosed amount in funding. The company has 3411 active competitors, including 1154 funded and 816 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Cycle Pharma is a UK-based biopharma that works on small molecule drug reformulation and repurposing for orphan indications. In Aug.2017, they received FDA approval for their lead candidate, NITYR (nitisinone tablets), indicated for the rare genetic disease, Hereditary Tyrosinemia type 1 (HT-1). The formulation does not require refrigeration and can be dissolved in water for pediatric patients. The company also manufactures generics.
- Website
- cyclepharma.com
- Social
- Email ID
- *****@cyclepharma.com
- Phone Number
- +44 **********
Key Metrics
Founded Year
2012
Location
Cambridge, United Kingdom
Stage
Funding Raised
Latest Funding Round
Investors
Ranked
200th among 3411 active competitors
Annual Revenue
£100M - £500M as on Dec 31, 2024
Employee Count
232 as on Jul 31, 2026
Investment & Acquisitions
Similar Companies
Legal entities associated with Cycle Pharma
Cycle Pharma is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Cycle Pharmaceuticals Ltd CIN: 7933058 , Germany, Active | Feb 01, 2012 | £100M - £500M (As on Dec 31, 2024) | 54 (As on Dec 31, 2021) |
Sign up to download Cycle Pharma's company profile
Cycle Pharma's funding and investors
Cycle Pharma has raised funding over 1 round. Its latest funding round was a Conventional Debt round on Sep 07, 2020 for $*****. 1 investor participated in its latest round. Cycle Pharma has 7 institutional investors and 26 angel investors.
Here is the list of recent funding rounds of Cycle Pharma:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Sep 07, 2020 | 3775004 | Conventional Debt | 2812525 | 2318196 | 7793003 | 1511177 |
Access funding benchmarks and valuations. Sign up today!View details of Cycle Pharma's funding rounds and investors
Cycle Pharma's founders and board of directors
Founder? Claim ProfileCycle Pharma's employee count trend
Cycle Pharma has 232 employees as of Jul 26. Here is Cycle Pharma's employee count trend over the years:
Uncover Cycle Pharma's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Cycle Pharma's Competitors and alternates
Top competitors of Cycle Pharma include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Cycle Pharma, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | BioMarin Pharmaceutical 1997, San Rafael (United States), Public | Developer of therapeutics for the treatment of rare genetic diseases | $37.5M | 72/100 | |
6th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
7th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
8th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
9th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 72/100 | |
10th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
200th | Cycle Pharma 2012, Cambridge (United Kingdom), Funding Raised | Small molecule drug reformulation and repurposing for orphan indications | - | 59/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Cycle Pharma's competitors? Click here to see the top ones
Cycle Pharma's Investments and acquisitions
Cycle Pharma has acquired 3 companies including Applied Therapeutics, Banner Life Sciences and Banner Life Sciences. Cycle Pharma has not made any investments as of now.Here is the list of its acquisitions:
Date of Investment/Acquisition | Type | Company Name | Founded Year | Location |
|---|---|---|---|---|
Dec 11, 2025 | Acquisition | 2015 | New York City (United States) | |
Jan 13, 2025 | Acquisition | 1994 | High Point (United States) | |
Oct 29, 2012 | Acquisition | 1994 | High Point (United States) |
Want to know more about where corporates are investing? Sign up today!Reports related to Cycle Pharma
Here is the latest report on Cycle Pharma's sector:
News related to Cycle Pharma
Filter this listMedia has covered Cycle Pharma for a total of 9 events in the last 1 year, 6 of them have been about company updates.
•
•
•
•
Cycle Group Holdings Acquires Applied TherapeuticsContract Pharma•Feb 03, 2026•Applied Therapeutics, Cycle Pharma
•
Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender OfferBusiness Wire•Jan 28, 2026•Cycle Pharma, Applied Therapeutics
•
Cycle Pharmaceuticals to Acquire Applied TherapeuticsBenzinga•Dec 12, 2025•Cycle Pharma, Applied Therapeutics
•
Onco360 Selected as Pharmacy Partner for PHYRAGO™ (dasatinib)GlobeNewswire•Oct 21, 2025•Onco360, Cycle Pharma
•
Cycle Pharmaceuticals Launches First Oncology Product PHYRAGO™ (dasatinib) Tablets in USBusiness Wire•Oct 16, 2025•Cycle Pharma
•
Cycle Pharmaceuticals selects LeMed as exclusive U.S. pharmacy partner for HARLIKU™Business Wire•Jul 21, 2025•Lemedrx, Cycle Pharma
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Cycle Pharma
Explore our recently published companies
- Himsons - Vadodara based, 1988 founded, Unfunded company
- Com2uS Platform Corp - Unfunded company
- Just Print - Unfunded company
